Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Hepatology

• Publication date

  2003-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0168-8278(03)00433-1PMID 14642604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.

  2002cited by this paper
• Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability.

  2001cited by this paper
• Genomic expression programs in the response of yeast cells to environmental changes.

  2000cited by this paper
• Comparison of oxidative stress response parameters in newborn mouse liver versus simian virus 40 (SV40)-transformed hepatocyte cell lines.

  2000cited by this paper
• A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice.

  2000cited by this paper
• Nontransplant treatment of tyrosinemia.

  2000cited by this paper
• Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis.

  2000cited by this paper
• Yap1 and Skn7 Control Two Specialized Oxidative Stress Response Regulons in Yeast*

  1999cited by this paper
• Cyclin B‐dependent kinase and caspase‐1 activation precedes mitochondrial dysfunction in fumarylacetoacetate‐induced apoptosis

  1999cited by this paper
• Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)

  1998cited by this paper
• The H2O2 Stimulon in Saccharomyces cerevisiae *

  1998cited by this paper
• Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors.

  1998cited by this paper
• Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.

  1997cited by this paper
• The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion.

  1997cited by this paper
• Abnormal glutathione conjugation in patients with tyrosinaemia type I

  1997cited by this paper
• Complete Rescue of Lethal Albino c 14CoS Mice by Null Mutation of 4-Hydroxyphenylpyruvate Dioxygenase and Induction of Apoptosis of Hepatocytes in These Mice by in VivoRetrieval of the Tyrosine Catabolic Pathway*

  1997cited by this paper
• Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries.

  1996cited by this paper
• Variable gene expression within human tyrosinemia type 1 liver may reflect region‐specific dysplasia

  1996cited by this paper
• Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I

  1995cited by this paper
• Disorders of mitochondrial long-chain fatty acid oxidation

  1995cited by this paper
• Hereditary tyrosinemia type I: A new clinical classification with difference in prognosis on dietary treatment

  1994cited by this paper
• Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice.

  1993cited by this paper
• Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type 1.

  1993cited by this paper
• Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

  1992cited by this paper
• Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice.

  1992cited by this paper
• Two genetically defined trans-acting loci coordinately regulate overlapping sets of liver-specific genes.

  1990cited by this paper
• Hereditary tyrosinemias (type I): a new vista on tyrosine toxicity and cancer.

  1986cited by this paper
• Hereditary tyrosinemia type I--an overview.

  1986cited by this paper
• Hereditary tyrosinemia type I--an overview.

  1986cited by this paper
• Biochemical Studies of a Patient with Hereditary Hepatorenal Tyrosinemia: Evidence of Glutathione Deficiency

  1984cited by this paper

• An engineered Escherichia coli Nissle strain prevents lethal liver injury in a mouse model of tyrosinemia type 1.

  2023cites this paper
• Carcinoma of the Liver in Children and Adolescents

  2021cites this paper
• Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I

  2021cites this paper
• Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1

  2019cites this paper
• Pediatric hepatocellular carcinoma

  2018cites this paper
• Nitisinone: A review

  2017cites this paper
• General Criteria for Transplantation in Children

  2015cites this paper
• Molecular changes associated with chronic liver damage and neoplastic lesions in a murine model of hereditary tyrosinemia type 1.

  2015cites this paper
• Clinical and Biochemical Profile of Tyrosinemia Type 1 in Tunisia.

  2015cites this paper
• Heat Shock Response Associated with Hepatocarcinogenesis in a Murine Model of Hereditary Tyrosinemia Type I

  2014cites this paper
• Efeito da administração aguda e crônica de L-tirosina sobre parâmetros de estresse oxidativo em fígado e em cérebro de ratos jovens

  2013cites this paper
• Chapter 18 – Neonatal Cholestasis

  2012cites this paper
• Nitisinone in the Treatment of Hereditary Tyrosinaemia Type 1

  2012cites this paper
• Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases

  2011cites this paper
• Paediatric liver transplantation for metabolic disorders. Part 2: Metabolic disorders with liver lesions.

  2011influential citation
• Inborn Errors of Metabolism

  2011cites this paper
• Tyrosinemia type I as a model for studying epigenetic events in the aetiology of metabolic disease associated hepatocarcinoma

  2011cites this paper
• High volume naked DNA tail‐vein injection restores liver function in Fah‐knock out mice

  2010cites this paper
• Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1

  2008cites this paper
• Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.

  2008cites this paper
• Chapter 9 – Cholestasis in Neonates and Infants

  2008cites this paper
• Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis.

  2008cites this paper
• Gene therapy for liver enzyme deficiencies: what have we learned from models for Crigler–Najjar and tyrosinemia?

  2007cites this paper
• Current Strategies for the Treatment of Hereditary Tyrosinemia Type I

  2006cites this paper
• Kidneys of Mice With Hereditary Tyrosinemia Type I Are Extremely Sensitive to Cytotoxicity

  2006cites this paper
• Involvement of Endoplasmic Reticulum Stress in Hereditary Tyrosinemia Type I*

  2006cites this paper
• Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.

  2006cites this paper
• Gene expression profiles of homogentisate-treated Fah-/- Hpd-/-mice using DNA microarrays.

  2006cites this paper
• Transcriptome Analysis of Paracoccidioides brasiliensis Cells Undergoing Mycelium-to-Yeast Transition

  2005cites this paper
• General Criteria for Pediatric Transplantation

  2005cites this paper
• In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery.

  2005cites this paper
• Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia.

  2005cites this paper
• In Vivo Correction of Murine Hereditary Tyrosinemia Type I by ϕC31 Integrase-Mediated Gene Delivery.

  2005cites this paper
• Diagnosis: Hereditary Type I Tyrosinema (hepatorenal tyrosinemia)

  2005cites this paper
• Hepatomegaly: commentary.

  2005cites this paper
• Delineating the Hepatocyte's Hematopoietic Fusion Partner

  2004cites this paper
• Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.

  2004cites this paper